Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia

Atherosclerosis Supplements

Volumn 14, Issue 2, 2013, Pages 237-242

  Pirillo, Angela ^a,b   Catapano, Alberico L ^b,c  

^a Bassini Hospital   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Dyslipidemia; Hypertriglyceridemia; Omega 3 polyunsaturated fatty acids; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; DOCOSAHEXAENOIC ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; DYSLIPIDEMIAS; TREATMENT OUTCOME;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; HUMANS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84881638012     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/S1567-5688(13)70004-7     Document Type: Article

References (47)

1. Schwartz EA, Reaven PD Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta 2012, 1821:858-866.
2. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
3. Hokanson JE, Austin MA Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
4. Cullen P Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000, 86:943-949.
5. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Jama 2007, 298:299-308.
6. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG Nonfasting triglycerides and risk of ischemic stroke in the general population. Jama 2008, 300:2142-2152.
7. Labreuche J, Touboul PJ, Amarenco P Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 2009, 203:331-345.
8. Morrison A, Hokanson JE The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag 2009, 5:89-95.
9. Jacobs DR, Barrett-Connor E Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982, 116:878-885.
10. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
11. Boullart AC, de Graaf J, Stalenhoef AF Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 2012, 1821:867-875.
12. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012, 97:2969-2989.
13. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
14. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997, 4:385-391.
15. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197:12-24.
16. Jacobson TA, Glickstein SB, Rowe JD, Soni PN Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012, 6:5-18.
17. Wei MY, Jacobson TA Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011, 13:474-483.
18. Jacobson TA Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 2008, 87:1981S-1990S.
19. Woodman RJ, Mori TA, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 2003, 26:253.
20. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000, 148:387-396.
21. Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009, 136:4-16.
22. Burillo E, Martin-Fuentes P, Mateo-Gallego R, et al. Omega-3 Fatty Acids and HDL. How Do They Work in the Prevention of Cardiovascular Disease?. Curr Vasc Pharmacol 2012, 10:432-441.
23. Chan DC, Watts GF, Nguyen MN, Barrett PH Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr 2006, 84:37-43.
24. Frenais R, Ouguerram K, Maugeais C, et al. Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis 2001, 157:131-135.
25. Burillo E, Mateo-Gallego R, Cenarro A, et al. Beneficial effects of omega-3 fatty acids in the proteome of high-density lipoprotein proteome. Lipids Health Dis 2012, 11:116.
26. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999, 143:285-297.
27. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova®) compared to Lovaza®) in a pharmacokinetic single-dose evaluation) study. J Clin Lipidol 2012, 6:573-584.
28. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011, 108:682-690.
29. Bays HE, Braeckman RA, Ballantyne CM, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol 2012, 6:565-572.
30. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012, 110:984-992.
31. Maki KC, Lawless AL, Kelley KM, et al. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol 2011, 57:489-494.
32. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
33. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135-140.
34. Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol 2009, 3:33-38.
35. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354-1367.
36. Vecka M, Dusejovska M, Stankova B, et al. N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuro Endocrinol Lett 2012, 33(Suppl 2):87-92.
37. Bays HE, McKenney J, Maki KC, et al. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 2010, 85:122-128.
38. Roth EM, Bays HE, Forker AD, et al. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. J Cardiovasc Pharmacol 2009, 54:196-203.
39. Shearer GC, Pottala JV, Hansen SN, Brandenburg V, Harris WS Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res 2012, 53:2429-2435.
40. Watts GF, Karpe F Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011, 97:350-356.
41. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007, 50:1593-1602.
42. Hartweg J, Farmer AJ, Holman RR, Neil A Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol 2009, 20:30-38.
43. Kazemian P, Kazemi-Bajestani SM, Alherbish A, Steed J, Oudit GY The use of omega-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes. Cardiovasc Drugs Ther 2012, 26:311-320.
44. Poole CD, Halcox JP, Jenkins-Jones S, et al. Omega-3 Fatty Acids and Mortality Outcome in Patients With and Without Type 2 Diabetes After Myocardial Infarction: A Retrospective, Matched-Cohort Study. Clin Ther 2012.
45. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003, 107:1852-1857.
46. Kromhout D, Geleijnse JM, de Goede J, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care 2011, 34:2515-2520.
47. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367:309-318.